BACKGROUND: Interpreting human immunodeficiency virus type 1 (HIV-1) genotypic drug-resistance test results is challenging for clinicians treating HIV-1-infected patients. Multiple drug-resistance interpretation algorithms have been developed, but their predictive value has rarely been evaluated using contemporary clinical data sets. METHODS: We examined the predictive value of 4 algorithms at predicting virologic response (VR) during 734 treatment-change episodes (TCEs). VR was defined as attaining plasma HIV-1 RNA levels below the limit of quantification. Drug-specific genotypic susceptibility scores (GSSs) were calculated by applying each algorithm to the baseline genotype. Weighted GSSs were calculated by multiplying drug-specific GSSs by antiretroviral (ARV) potency factors. Regimen-specific GSSs (rGSSs) were calculated by adding unweighted or weighted drug-specific GSSs for each salvage therapy ARV. The predictive value of rGSSs were estimated by use of multivariate logistic regression. RESULTS: Of 734 TCEs, 475 (65%) were associated with VR. The rGSSs for the 4 algorithms were the variables most strongly predictive of VR. The adjusted rGSS odds ratios ranged from 1.6 to 2.2 (P < .001). Using 10-fold cross-validation, the averaged area under the receiver operating characteristic curve for all algorithms increased from 0.76 with unweighted rGSSs to 0.80 with weighted rGSSs. CONCLUSIONS: Unweighted and weighted rGSSs of 4 genotypic resistance algorithms were the strongest independent predictors of VR. Optimizing ARV weighting may further improve VR predictions.
BACKGROUND: Interpreting humanimmunodeficiency virus type 1 (HIV-1) genotypic drug-resistance test results is challenging for clinicians treating HIV-1-infectedpatients. Multiple drug-resistance interpretation algorithms have been developed, but their predictive value has rarely been evaluated using contemporary clinical data sets. METHODS: We examined the predictive value of 4 algorithms at predicting virologic response (VR) during 734 treatment-change episodes (TCEs). VR was defined as attaining plasma HIV-1 RNA levels below the limit of quantification. Drug-specific genotypic susceptibility scores (GSSs) were calculated by applying each algorithm to the baseline genotype. Weighted GSSs were calculated by multiplying drug-specific GSSs by antiretroviral (ARV) potency factors. Regimen-specific GSSs (rGSSs) were calculated by adding unweighted or weighted drug-specific GSSs for each salvage therapy ARV. The predictive value of rGSSs were estimated by use of multivariate logistic regression. RESULTS: Of 734 TCEs, 475 (65%) were associated with VR. The rGSSs for the 4 algorithms were the variables most strongly predictive of VR. The adjusted rGSS odds ratios ranged from 1.6 to 2.2 (P < .001). Using 10-fold cross-validation, the averaged area under the receiver operating characteristic curve for all algorithms increased from 0.76 with unweighted rGSSs to 0.80 with weighted rGSSs. CONCLUSIONS: Unweighted and weighted rGSSs of 4 genotypic resistance algorithms were the strongest independent predictors of VR. Optimizing ARV weighting may further improve VR predictions.
Authors: Françoise Brun-Vézinet; Dominique Costagliola; Mounir Ait Khaled; Vincent Calvez; François Clavel; Bonaventura Clotet; Richard Haubrich; Dale Kempf; Marty King; Daniel Kuritzkes; Randall Lanier; Michael Miller; Veronica Miller; Andrews Phillips; Deenan Pillay; Jonathan Schapiro; Janna Scott; Robert Shafer; Maurizio Zazzi; Andrew Zolopa; Victor DeGruttola Journal: Antivir Ther Date: 2004-08
Authors: Cristina Tural; Lidia Ruiz; Christopher Holtzer; Jonathan Schapiro; Pompeyo Viciana; Juan González; Pere Domingo; Charles Boucher; C Rey-Joly; Bonaventura Clotet Journal: AIDS Date: 2002-01-25 Impact factor: 4.177
Authors: A M Vandamme; A Sönnerborg; M Ait-Khaled; J Albert; B Asjo; L Bacheler; D Banhegyi; C Boucher; F Brun-Vézinet; R Camacho; P Clevenbergh; N Clumeck; N Dedes; A De Luca; H W Doerr; J L Faudon; G Gatti; J Gerstoft; W W Hall; A Hatzakis; N Hellmann; A Horban; J D Lundgren; D Kempf; M Miller; V Miller; T W Myers; C Nielsen; M Opravil; L Palmisano; C F Perno; A Phillips; D Pillay; T Pumarola; L Ruiz; M Salminen; J Schapiro; B Schmidt; J C Schmit; R Schuurman; E Shulse; V Soriano; S Staszewski; S Vella; M Youle; R Ziermann; L Perrin Journal: Antivir Ther Date: 2004-12
Authors: J D Baxter; D L Mayers; D N Wentworth; J D Neaton; M L Hoover; M A Winters; S B Mannheimer; M A Thompson; D I Abrams; B J Brizz; J P Ioannidis; T C Merigan Journal: AIDS Date: 2000-06-16 Impact factor: 4.177
Authors: Silvia Baroncelli; Clementina Maria Galluzzo; Liliana Elena Weimer; Maria Franca Pirillo; Anna Volpe; Alessandra Mercuri; Albertina Cavalli; Vincenzo Fragola; Laura Monno; Anna Degli Antoni; Nicoletta Ladisa; Daniela Francisci; Raffaella Bucciardini; Marco Floridia Journal: J Antimicrob Chemother Date: 2012-02-23 Impact factor: 5.790
Authors: Jeanette M Tetrault; Michael J Kozal; Jennifer Chiarella; Lynn E Sullivan; An T Dinh; David A Fiellin Journal: J Addict Med Date: 2013 Mar-Apr Impact factor: 3.702
Authors: Silvia Baroncelli; Maria Franca Pirillo; Clementina Maria Galluzzo; Anna Degli Antoni; Nicoletta Ladisa; Daniela Francisci; Gabriella d'Ettorre; Daniela Segala; Angela Vivarelli; Federica Sozio; Oscar Cirioni; Liliana Elena Weimer; Vincenzo Fragola; Giustino Parruti; Marco Floridia Journal: AIDS Res Hum Retroviruses Date: 2015-01 Impact factor: 2.205
Authors: Dineke Frentz; Charles A B Boucher; Matthias Assel; Andrea De Luca; Massimiliano Fabbiani; Francesca Incardona; Pieter Libin; Nino Manca; Viktor Müller; Breanndán O Nualláin; Roger Paredes; Mattia Prosperi; Eugenia Quiros-Roldan; Lidia Ruiz; Peter M A Sloot; Carlo Torti; Anne-Mieke Vandamme; Kristel Van Laethem; Maurizio Zazzi; David A M C van de Vijver Journal: PLoS One Date: 2010-07-09 Impact factor: 3.240
Authors: Soo-Yon Rhee; Jose Luis Blanco; Tommy F Liu; Iñaki Pere; Rolf Kaiser; Maurizio Zazzi; Francesca Incardona; William Towner; Josep Maria Gatell; Andrea De Luca; W Jeffrey Fessel; Robert W Shafer Journal: AIDS Res Ther Date: 2012-05-03 Impact factor: 2.250
Authors: Mattia C F Prosperi; Simona Di Giambenedetto; Iuri Fanti; Genny Meini; Bianca Bruzzone; Annapaola Callegaro; Giovanni Penco; Patrizia Bagnarelli; Valeria Micheli; Elisabetta Paolini; Antonio Di Biagio; Valeria Ghisetti; Massimo Di Pietro; Maurizio Zazzi; Andrea De Luca Journal: BMC Med Inform Decis Mak Date: 2011-06-14 Impact factor: 2.796